Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
GT-02287 Well Tolerated With No Serious Adverse Events or Other Safety Signals Reported Additional Topline Data To Be Presented Mid-August GT-02287 on Track To Initiate Clinical Trial in...
-
BETHESDA, Md., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have...
-
Data from Patient-Derived iPSC Study Evaluating STAR Compounds Show Positive Effects on Disease Onset and Progression; Full Data Presented at MJFF’s Parkinson's Disease Therapeutics Conference---...
-
BETHESDA, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding...
-
Study results demonstrate first small molecule approach to significantly reduce phosphorylated and aggregated -synuclein and increase GCase protein levels with transport to the lysosomes in iPSC...
-
In-Person Dates: November 16th-17thVirtual Dates: November 18th-19th BETHESDA, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a...
-
- The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Webinars - - Society of Neuroscience 50th Anniversary Meeting – BETHESDA, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Gain...
-
BETHESDA, Md., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “company”), a biotechnology company focused on identifying and optimizing allosteric binding...
-
BETHESDA, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding...
-
BETHESDA, Md., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding...